Roche’s Gazyva shows strong phase III results for treatment of idiopathic nephrotic syndrome
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Allergan Aesthetics reaffirms commitment to empowering girls through STEM mentorship and education initiatives
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
In the next five years, an additional 75,000 seats are expected to be added across both undergraduate and postgraduate levels
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Subscribe To Our Newsletter & Stay Updated